latest news releases from the newsroom
Fredrik Brunell new CFO of Volvo Aero
GOTEBORG, Sweden, Oct. 17, 2005 (PRIMEZONE) -- Fredrik Brunell, Investor Relations Manager at Volvo, has been appointed new Chief Financial Officer of Volvo Aero. The new Investor Relations Manager will be Christer Johansson. Both will assume their new positions on December 1.
Tele2 Halts Any Further Investments in Its Fixed Line Operations in Estonia, Latvia and Lithuania
STOCKHOLM, Sweden, Oct. 17, 2005 (PRIMEZONE) -- Tele2 AB, ("Tele2"), (Stockholmsborsen:TEL2A) and (Stockholmsborsen:TEL2B), the leading alternative pan-European telecommunications company, today announced that, based on the current regulatory environment in Estonia, Latvia and Lithuania, it has decided to stop any further investments in its fixed line operations in these countries.
Impac Announces New Vice President, Professional Services
MOUNTAIN VIEW, Calif. and STOCKHOLM, Sweden, Oct. 17, 2005 (PRIMEZONE) -- IMPAC Medical Systems, Inc., part of the Elekta Group and a leading provider of information technology solutions for oncology care, has named Gerald L. (Gerry) Hogue as Vice President, Professional Services. Mr. Hogue was the founder of OpTx Corporation, formerly IMPAC's major competitor in the medical oncology arena. He brings significant oncology and pharmaceutical market knowledge and access, and rich functional skills and methodologies in oncology and IT management, systems implementation, process change management and clinical trials to IMPAC/Elekta.
Saab and Boeing Signs Contract for 787 Dreamliner
LINKOPING, Sweden, Oct. 17, 2005 (PRIMEZONE) -- Saab Aerostructures has signed a contract with The Boeing Company concerning the design, development and manufacturing of Large Cargo Doors, Bulk Cargo Door and Access Doors for the Boeing 787 Dreamliner. The order value is initially estimated at $100 million. Revenues over the lifetime of the agreement are expected to reach a multi-million dollar level.
Antisoma Announces Promising Preliminary Phase II Data for AS1404 in Lung Cancer
LONDON, Oct. 17, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) today announces preliminary findings from an ongoing phase II trial of AS1404 in lung cancer. With initial data available from 47 of the 71 patients enrolled, those receiving AS1404 in addition to chemotherapy showed a higher frequency of tumour responses (43.5% vs 33.3%) and a lower frequency of progressive disease (8.7% vs 33.3%) than those receiving chemotherapy alone. Details are provided below. To date, all safety findings in the AS1404 arm of the trial have been consistent with those observed with standard chemotherapy treatment.